Fusion IP portfolio co Diurnal raises £335000 for developing lead product ... Proactive Investors USA & Canada Based in Cardiff, Diurnal is developing a novel approach to drug delivery that will help patients suffering from reduced levels of the key hormone cortisol (hydrocortisone). Chronocort is a modified release therapy that delivers hydrocortisone in a ... |
